RxDoctor Payments Data

Byron Wilkes, MD

Ophthalmology · Pine Bluff, ARNPI 1710101977

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Amgen at 39.5% of the total. Reporting peaked in 2024 at $422 and has fallen 69.1% since, to $130 in 2025.

$1,238in general payments, 2019–2025

Across 56 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$489
  • AbbVie$256
  • Alcon$169
  • Bausch & Lomb Americas Inc.$79
  • Sun Pharmaceutical Industries Inc.$44
  • Mallinckrodt Hospital Products Inc.$44
  • plus $158 from 7 others
$57,117in research payments, 2019–2025

Across 2 payments — averaging $28,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$57K

What the payments were for

  • Food & beverage$1,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 65th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$529,014
Medicare patients
874
Services billed
10,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErythromycinErythromycin Base807$8,494
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen539$1,643
Prednisolone Acetate55$1,542
Bacitracin14$1,189
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha47$535
Doxycycline Hyclate18$481
Tramadol Hcl34$67
Cephalexin13$50
Ondansetron OdtOndansetron14$48

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →